국소 재발한 두경부암의 치료

키워드

참고문헌 (58)

1. Mody MD, "Head and neck cancer", Lancet, 398(10318), pp.2289~2299 (2021)
2. Cohen N, "Epidemiology and demographics of the head and neck cancer population", Oral Maxillofac Surg Clin North Am, 30(4), pp.381~395 (2018)
3. Pernot M, "The study of tumoral, radiobiological, and general health factors that influence results and complications in a series of 448oral tongue carcinomas treated exclusively by irradiation", Int J Radiat Oncol Biol Phys, 29(4), pp.673~679 (1994)
4. Calais G, "Radiotherapy with concomitant weekly docetaxel for stages III", IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial, 2004, pp.58(1), 161~166
5. Lefebvre JL, "Larynx preservation in pyriform sinus cancer:Preliminary results of a European Organization for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group", J Natl Cancer Inst, 88(13), pp.890~899 (1996)
6. Cooper JS, "Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck", N Engl J Med, 350(19), pp.1937~1944 (2004)
7. Bernier J, "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer", N Engl J Med, 350(19), pp.1945~1952 (2004)
8. Bernier J, "Defining risk levels in locally advanced head and neck cancers : A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC(#22931)and RTOG(# 9501)", Head Neck, 27(10), pp.843~850 (2005)
9. "Head and neck cancers. NCCN guidelines version 1" (2022)[URL]
10. Rosenberg AJ, "Optimizing treatment de-escalation in head and neck cancer : Current and future perspectives", Oncologist, 26(1), pp.40~48 (2021)
11. Golusinski P, "De-escalation studies in HPV-positive oropharyngeal cancer : How should we proceed?", Oral Oncol, 123, pp.105620~ (2021)
12. Zenga J, "Salvage of recurrence after surgery and adjuvant therapy : A systematic review", Am J Otolaryngol, 39(2), pp.223~227 (2018)
13. Kwon D, "Overcoming wound complications in head and neck salvage surgery", Auris Nasus Larynx, 45(6), pp.1135~1142 (2018)
14. Weiss F, "Towards targeting of shared mechanisms of cancer metastasis and therapy resistance", Nat Rev Cancer, 22(3), pp.157~173 (2022)
15. Fisher MD, "Effectiveness outcomes in patients with recurrent or refractory head and neck cancers : Retrospective analysis of data from a community oncology database", Clin Ther, 40(9), pp.1522~1537 (2018)
16. Fisher MD, "Patient characteristics and costs in recurrent or refractory head and neck cancer : Retrospective analysis of a community oncology database", Clin Ther, 40(4), pp.562~573 (2018)
17. Hedberg ML, "Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma", J Clin Invest, 126(1), pp.169~180 (2016)
18. de Roest RH, "Molecular characterization of locally relapsed head and neck cancer after concomitant chemoradiotherapy", Clin Cancer Res, 25(23), pp.7256~7265 (2019)
19. Barker HE, "The tumour microenvironment after radiotherapy : Mechanisms of resistance and recurrence", Nat Rev Cancer, 15(7), pp.409~425 (2015)
20. Watermann C, "Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion", Clin Cancer Res, 27(2), pp.632~644 (2021)
21. Matzner P, "Harnessing cancer immunotherapy during the unexploited immediate perioperative period", Nat Rev Clin Oncol, 17(5), pp.313~326 (2020)
22. Kwon M, "The right timing, right combination, right sequence, and right delivery for cancer immunotherapy", J Control Release, 331, pp.321~334 (2021)
23. Mehanna H, "Recurrent head and neck cancer : United Kingdom National Multidisciplinary Guidelines", J Laryngol Otol, 130(S2), pp.S181~S190 (2016)
24. Jayaram SC, "Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent", residual oropharyngeal carcinoma: A systematic review and meta-analysis, 2016, pp.38(12), 1855~1861
25. Weber RS, "Outcome of salvage total laryngectomy following organ preservation therapy : The Radiation Therapy Oncology Group trial 91-11", Arch Otolaryngol Head Neck Surg, 129(1), pp.44~49 (2003)
26. Hasan Z, "Systematic review and meta-analysis of the complications of salvage total laryngectomy", Eur J Surg Oncol, 43(1), pp.42~51 (2017)
27. Taussky D, "Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas", Head Neck, 27(3), pp.182~186 (2005)
28. Temam S, "Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma", Int J Radiat Oncol Biol Phys, 62(4), pp.1078~1083 (2005)
29. Elbers JBW, "Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation", Eur Arch Otorhinolaryngol, 276(3), pp.647~655 (2019)
30. Hamoir M, "The current role of salvage surgery in recurrent head and neck squamous cell carcinoma", Cancers(Basel), 10(8), pp.267~ (2018)
31. Cacicedo J, "The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach", Cancer Treat Rev, 40(1), pp.178~189 (2014)
32. Lee N, "Salvage re-irradiation for recurrent head and neck cancer", Int J Radiat Oncol Biol Phys, 68(3), pp.731~740 (2007)
33. Dionisi F, "Organs at risk’s tolerance and dose limits for head and neck cancer re-irradiation : A literature review", Oral Oncol, 98, pp.35~47 (2019)
34. Haraf DJ, "Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer : A potentially curable disease", Ann Oncol, 7(9), pp.913~918 (1996)
35. De Crevoisier R, "Full-dose reirradiation for unresectable head and neck carcinoma : Experience at the Gustave-Roussy Institute in a series of 169 patients", J Clin Oncol, 16(11), pp.3556~3562 (1998)
36. Langendijk JA, "A phase II study of primary reirradiation in squamous cell carcinoma of head and neck", Radiother Oncol, 78(3), pp.306~312 (2006)
37. Lee J, "Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer : Meta-analysis and systematic review", Head Neck, 42(9), pp.2473~2485 (2020)
38. Lee J, "Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer : A meta-analysis and systematic review", Oral Oncol, 107, pp.104757~ (2020)
39. Svajdova M, "Radical external beam reirradiation in the treatment of recurrent head and neck cancer : Critical review", Head Neck, 43(1), pp.354~366 (2021)
40. Phan J, "Reirradiation of head and neck cancers with proton therapy : Outcomes and analyses", Int J Radiat Oncol Biol Phys, 96(1), pp.30~41 (2016)
41. Gordon K, "Proton re-irradiation of unresectable recurrent head and neck cancers", Rep Pract Oncol Radiother, 26(2), pp.203~210 (2021)
42. Gao J, "Salvage carbonion radiation therapy for locoregionally recurrent head and neck malignancies", Sci Rep, 9(1), pp.4259~ (2019)
43. Held T, "Carbon ion reirradiation for recurrent head and neck cancer : A single-institutional experience", Int J Radiat Oncol Biol Phys, 105(4), pp.803~811 (2019)
44. Wong SJ, "Locally recurrent, previously irradiated head and neck cancer: Concurrent re-irradiation and chemotherapy, or chemotherapy alone?", J Clin Oncol, 24(17), pp.2653~2658 (2006)
45. Dewhirst MW, "Transport of drugs from blood vessels to tumour tissue", Nat Rev Cancer, 17(12), pp.738~750 (2017)
46. Hao Z, "Lenvatinib in management of solid tumors", Oncologist, 25(2), pp.e302~e310 (2020)
47. Grünwald V, "Global treatment patterns and outcomes among patients with recurrent and", or metastatic head and neck squamous cell carcinoma : Results of the GLANCE H&N study, 2020, pp.102, 104526~
48. Guidi A, "Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer : A systematic review", Med Oncol, 35(3), pp.37~ (2018)
49. Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359(11), pp.1116~1127 (2008)
50. Mesía R, "Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and", or metastatic squamous cell carcinoma of the head and neck, 2010, pp.21(10), 1967~1973
51. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375(19), pp.1856~1867 (2016)
52. Cohen EEW, "Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study", Lancet, 393(10167), pp.156~167 (2019)
53. Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):A randomised, open-label, phase 3 study", Lancet, 394(10212), pp.1915~1928 (2019)
54. Rodin J, "A systematic review of treating recurrent head and neck cancer : A reintroduction of brachytherapy with or without surgery", J Contemp Brachytherapy, 10(5), pp.454~462 (2018)
55. Lou PJ, "Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer", Br J Cancer, 91(3), pp.441~446 (2004)
56. Meulemans J, "Photodynamic therapy in head and neck cancer: Indications, outcomes, and future prospects", Curr Opin Otolaryngol Head Neck Surg, 27(2), pp.136~141 (2019)
57. Li X, "Clinical development and potential of photothermal and photodynamic therapies for cancer", Nat Rev Clin Oncol, 17(11), pp.657~674 (2020)
58. Alzeibak R, "Targeting immunogenic cancer cell death by photodynamic therapy : Past, present and future", J Immunother Cancer, 9(1), pp.e001926~ (2021)

관련 논문AI추천